Open-Label Extension of EryDex Study IEDAT-04-2022
Status:
RECRUITING
Trial end date:
2026-11-30
Target enrollment:
Participant gender:
Summary
This is an international, multi-center, prospective, open-label, non-comparative study to provide EryDex treatment to ataxia telangiectasia (A-T) patients who complete the IEDAT-04-2022 trial on the neurological effects of EryDex on subjects with ataxia telangiectasia (NEAT trial).